EOLS
Evolus, Inc.
Latest Form 4:Sale$65KbyMOATAZEDI DAVID (See Remarks) · filed Mar 20, 2026
Evolus, Inc. (EOLS) has 15 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Mar 20, 2026.
The most active filer is See Remarks MOATAZEDI DAVID with 3 filings. Insiders have net sold $888K over the trailing 6 months.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:David Moatazedi
- Employees:350
- HQ:Newport Beach, CA, US
- IPO:2018-02-08
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$888K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| See Remarks | Sale | 13,669 | $65K | Mar 20 | SEC ↗ | |
| See Remarks | Sale | 3,119 | $15K | Mar 20 | SEC ↗ | |
| See Remarks | Sale | 29,996 | $147K | Mar 18 | SEC ↗ | |
| See Remarks | Sale | 116,720 | $571K | Mar 18 | SEC ↗ | |
Avelar RuiFirst filing | See Remarks | Sale | 2,261 | $16K | Dec 29 | SEC ↗ |
MOATAZEDI DAVIDFirst filing | See Remarks | Sale | 10,539 | $75K | Dec 29 | SEC ↗ |
Related companies
Evolus, Inc. is in the Healthcare sector.